KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer.
about
Recent Advances in Chemotherapy and Surgery for Colorectal Liver MetastasesSurgical Management of Colorectal Liver Metastases: Prognostic Indicators and the Impact of RAS Mutation StatusConcordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastasesMutational analysis and clinical correlation of metastatic colorectal cancer.Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases.Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study.Predictors of Safety and Efficacy of 2-Stage Hepatectomy for Bilateral Colorectal Liver Metastases.RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.Paired Primary and Metastatic Tumor Analysis of Somatic Mutations in Synchronous and Metachronous Colorectal Cancer.The Report of KRAS Mutation and NRAS Wild Type in a Patient with Thyroid Metastasis from Colon Cancer: a Rare Case Report.Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients.Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.KRAS mutation status is highly homogeneous between areas of the primary tumor and the corresponding metastasis of colorectal adenocarcinomas: one less problem in patient care.RAS mutations vary between lesions in synchronous primary colorectal cancer: testing only one lesion is not sufficient to guide anti-EGFR treatment decisions.KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary.From multidisciplinary to personalized treatment of colorectal liver metastases: 4 reasons to consider RAS.Reply: KRAS mutation in colorectal cancer metastases after adjuvant folfox for the primary.Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by ComprehenMonitoring circulating tumor DNA revealed dynamic changes in KRAS status in patients with metastatic colorectal cancer.
P2860
Q28067408-07F2FD35-D832-4880-A797-B35C0CF8FFA2Q28075777-59B41031-BBB8-4155-903C-73D64D88BC21Q28088489-8A1FD172-7ACF-4ED6-9805-560B8886FC2FQ35082873-CAAD6E49-7C30-40E9-80D4-631FCD114BA4Q35183160-7573FCE1-A6C3-4554-B7F0-6C22930C50FBQ35709696-A12CD3AB-2D5B-41E6-94B5-0827394AA6C9Q35800764-42410A31-7AC3-455A-BF50-1ACA9BEE0074Q37047788-3E0B60F3-35A7-4E75-9EDB-6AFE0FCE9E8CQ37375848-C89ACABF-73FB-4E7A-B7BF-63ACB8A8536CQ37606706-BE84EA55-0AD0-49D0-932B-054107F04C86Q38352014-DC3CD398-B33F-44B7-93AD-0DA24A14BAC9Q39704299-7FC0651D-6C14-4649-A723-560CE027BA90Q40674654-6357872D-4BA8-4BF4-9B41-A25BA2F721D7Q41980098-A5E7498B-C149-4DFB-ADCE-E55CFD447E57Q42139232-A3404CD9-FF4A-4463-BCBD-672EF00F85F9Q42350666-1AEC52F0-9F52-43A5-AED4-484761D7826CQ44751710-7CDCE4D9-1078-4AB0-8873-5EDDD3B41CF1Q45940227-B47CDF10-E9FA-4DFC-B986-460E6A97D65FQ47109685-C5A34DB9-270C-416A-A96E-B62A9042A561Q55347051-7CED5B53-38B7-4795-ABCD-D837FAF4E596
P2860
KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
KRAS mutations in primary tumo ...... in cases of colorectal cancer.
@ast
KRAS mutations in primary tumo ...... in cases of colorectal cancer.
@en
type
label
KRAS mutations in primary tumo ...... in cases of colorectal cancer.
@ast
KRAS mutations in primary tumo ...... in cases of colorectal cancer.
@en
prefLabel
KRAS mutations in primary tumo ...... in cases of colorectal cancer.
@ast
KRAS mutations in primary tumo ...... in cases of colorectal cancer.
@en
P2093
P2860
P356
P1476
KRAS mutations in primary tumo ...... in cases of colorectal cancer.
@en
P2093
K Tsuchihara
M Takahashi
N Ogasawara
P2860
P2888
P304
P356
10.1038/BJC.2012.218
P407
P577
2012-05-22T00:00:00Z
P5875
P6179
1026868768